All the experiments were in accordance with protocols approved by the Institutional Animal Care and Use Committee of Stanford University and were performed based on the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Adult B6SJL Tg (SOD1G93A) 1 Gur/J male mice with a high copy number of the mutant allele and their WT littermates were purchased from the Jackson laboratory (Maine) at the age of 4–6 weeks. The animals used in the P110 treatment study were implanted with a 28‐day osmotic pump (Alzet) slightly posterior to the scapulae containing TAT47–57 carrier control peptide or P110‐TAT47–57, which delivered to the mice at a rate of 3 mg/Kg/day, as described previously (Disatnik et al, 2016). The first pump was implanted at an average age of 90 days, when the animals showed clinical symptoms, with the subsequent pump implantation 30 days later, when mice were ~120 days old.